The long-term objectives of this research plan are to study and define the mechanisms of regulation of the normal arginine vasopressin (AVP) gene and the altered AVP gene in central diabetes insipidus. The regulation of AVP release will be evaluated under osmotic and non-osmotic stimulation. The specific hypothesis of the proposed research are as follows: 1. Specific structural features of the three domains of the AVP precursor (AVP, neurophysin, and glycopeptide) are necessary for the transport, processing and subsequent secretion of mature AVP. The protocols outlined in this proposal will define the region necessary for normal secretion of mature AVP from the cell and the processing defect with occurs in central diabetes insipidus in the Brattleboro rat. 2. Each regulatory element located in the promoter region of the AVP gene (CRE, GRE, AP2) has a specific role in the regulation of AVP gene expression. The described protocols will define the non-osmotic and osmotic regulation of this gene. The contribution of additional sites in the promoter region of the AVP gene to the regulation by these stimuli will also be assessed. The methods employed for these studies will include cell culture of COS cells and small cell lung cancer cells, mutagenesis, transfection, immunoprecipitation (pulse chase) immunofluorescence, measurement of AVP mRNA, and RIA of AVP. These studies should provide an understanding of the mechanisms of normal AVP secretion and the defect in hereditary central diabetes insipidus. Also the studies on the osmotic and non-osmotic controlling mechanisms of AVP gene expression will provide a greater understanding of AVP biosynthesis and release. The studies comprising this project are a logical molecular biological extension of this laboratory's long standing interest in the regulation of vasopressin release and action.

Project Start
1998-04-01
Project End
1999-03-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
20
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Li, Chunling; Wang, Weidong; Rivard, Christopher J et al. (2011) Molecular mechanisms of angiotensin II stimulation on aquaporin-2 expression and trafficking. Am J Physiol Renal Physiol 300:F1255-61
Andres-Hernando, Ana; Lanaspa, Miguel A; Li, Nanxing et al. (2010) Effects of 2-bromoethanamine on TonEBP expression and its possible role in induction of renal papillary necrosis in mice. Toxicol Sci 118:510-20
Furgeson, Seth B; Simpson, Peter A; Park, Insun et al. (2010) Inactivation of the tumour suppressor, PTEN, in smooth muscle promotes a pro-inflammatory phenotype and enhances neointima formation. Cardiovasc Res 86:274-82
Wang, Weidong; Li, Chunling; Summer, Sandra et al. (2010) Interaction between vasopressin and angiotensin II in vivo and in vitro: effect on aquaporins and urine concentration. Am J Physiol Renal Physiol 299:F577-84
Schrier, Robert W (2010) Systemic arterial vasodilation, vasopressin, and vasopressinase in pregnancy. J Am Soc Nephrol 21:570-2
Lanaspa, Miguel A; Andres-Hernando, Ana; Rivard, Christopher J et al. (2009) ZAC1 is up-regulated by hypertonicity and decreases sorbitol dehydrogenase expression, allowing accumulation of sorbitol in kidney cells. J Biol Chem 284:19974-81
Schrier, Robert W (2009) Interactions between angiotensin II and arginine vasopressin in water homeostasis. Kidney Int 76:137-9
Berl, Tomas (2009) How do kidney cells adapt to survive in hypertonic inner medulla? Trans Am Clin Climatol Assoc 120:389-401
Bansal, Shweta; Lindenfeld, JoAnn; Schrier, Robert W (2009) Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail 2:370-6
Schrier, Robert W; Masoumi, Amirali; Elhassan, Elwaleed (2009) Role of vasopressin and vasopressin receptor antagonists in type I cardiorenal syndrome. Blood Purif 27:28-32

Showing the most recent 10 out of 153 publications